Marketresearchnews: March 2018

Monday 26 March 2018

Cervical Intraepithelial Neoplasia (CIN) Industry Professional Survey About Therapeutics And Pipeline Review H1 2017

Overview
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555350-cervical-intraepithelial-neoplasia-cin-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 1 molecules, respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
CEL-SCI Corp
CritiTech Inc
Genexine Inc
PDS Biotechnology Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
THEVAX Genetics Vaccine USA Inc
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555350-cervical-intraepithelial-neoplasia-cin-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Global Presbyopia Industry Trends, Regulations And Competitive Landscape Outlook

Overview

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555348-presbyopia-pipeline-review-h1-2017

Report Highlights

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 1 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Table of Contents

List of Figures
Introduction
Global Markets Direct Report Coverage
Presbyopia - Overview
Presbyopia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Presbyopia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Presbyopia - Companies Involved in Therapeutics Development
Acucela Inc
Allergan Plc
Johnson & Johnson
Novartis AG
Presbyopia - Drug Profiles
(aceclidine + tropicamide) - Drug Profile

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555348-presbyopia-pipeline-review-h1-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Recent Study Explores Alpha Synuclein Industry Pipeline Review, H1 2018

Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 40 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 5, 20, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Alzheimer's Disease, Neurodegenerative Diseases, Amyloidosis, Constipation, Down Syndrome, Familial Amyloid Neuropathies, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Huntington Disease, Lewy body Dementia, Schizophrenia, Spinal Cord Injury, Traumatic Brain Injury and Type 2 Diabetes.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2966998-alpha-synuclein-non-a-beta-component-of-ad-amyloid-or
Major Scope of the report:
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2966998-alpha-synuclein-non-a-beta-component-of-ad-amyloid-or
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Global Integrin Beta 3 Industry Trends, Regulations And Competitive Landscape Outlook H1 2018

Overview

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Integrin Beta 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2966997-integrin-beta-3-platelet-membrane-glycoprotein-iiia-or-cd61-or
Report Highlights
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.
Major Scope of the report:
- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
- The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2966997-integrin-beta-3-platelet-membrane-glycoprotein-iiia-or-cd61-or
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Recent Study Explores Female Sexual Dysfunction Industry Pipeline Review, 2017

Overview

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555352-female-sexual-dysfunction-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 8, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Allergan Plc

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555352-female-sexual-dysfunction-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Recent Study Explores Rhino-Conjunctivitis Industry Pipeline Review, H1 2017

Overview

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555346-rhino-conjunctivitis-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 7, 8, 1 and 1 respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rhino-Conjunctivitis - Overview
Rhino-Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rhino-Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma GmbH & Co KG
Allergy Therapeutics Plc
ASIT Biotech SA
Astellas Pharma Inc
Bial - Portela & Ca SA

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555346-rhino-conjunctivitis-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Market Overview Of Melanoma Industry Clinical Trials Review, H1, 2017

Overview

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555344-melanoma-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 105, 120, 7, 214, 29 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 14, 13, 1, 62 and 14 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

Table of Contents

Table of Contents 2
Introduction 11
Melanoma - Overview 12
Melanoma - Therapeutics Development 13
Melanoma - Therapeutics Assessment 71
Melanoma - Companies Involved in Therapeutics Development 103
Melanoma - Drug Profiles 230
Melanoma - Dormant Projects 1675
Melanoma - Discontinued Products 1701
Melanoma - Product Development Milestones 1705
Appendix 1721

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555344-melanoma-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Prostate Cancer Industry Assessment And Therapeutics Analysis Forecasts To 2017

Overview

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555342-prostate-cancer-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 98, 108, 6, 247, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 15, 58 and 20 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.

Table of Contents

Table of Contents 2
Introduction 13
Prostate Cancer - Overview 14
Prostate Cancer - Therapeutics Development 15
Prostate Cancer - Therapeutics Assessment 78
Prostate Cancer - Companies Involved in Therapeutics Development 113
Prostate Cancer - Drug Profiles 263
Prostate Cancer - Dormant Projects 1732
Prostate Cancer - Discontinued Products 1763
Prostate Cancer - Product Development Milestones 1774
Appendix 1784

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555342-prostate-cancer-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Ovarian Cancer Market To Observe Strong Development By 2017

Overview

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555340-ovarian-cancer-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.

Table of Contents

Table of Contents 2
Introduction 12
Ovarian Cancer - Overview 13
Ovarian Cancer - Therapeutics Development 14
Ovarian Cancer - Therapeutics Assessment 73
Ovarian Cancer - Companies Involved in Therapeutics Development 105
Ovarian Cancer - Drug Profiles 254
Ovarian Cancer - Dormant Projects 1928
Ovarian Cancer - Discontinued Products 1947
Ovarian Cancer - Product Development Milestones 1951
Appendix 1968

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555340-ovarian-cancer-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Global Colorectal Cancer Industry Trends, Regulations And Competitive Landscape Outlook

Overview

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555338-colorectal-cancer-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 25, 108, 137, 10, 173, 26 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 18, 9, 28 and 5 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

Table of Contents

Table of Contents 2
Introduction 11
Colorectal Cancer - Overview 12
Colorectal Cancer - Therapeutics Development 13
Colorectal Cancer - Therapeutics Assessment 66
Colorectal Cancer - Companies Involved in Therapeutics Development 94
Colorectal Cancer - Drug Profiles 223
Colorectal Cancer - Dormant Projects 1708
Colorectal Cancer - Discontinued Products 1725
Colorectal Cancer - Product Development Milestones 1730
Appendix 1745

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555338-colorectal-cancer-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Recurrent Malignant Glioma Industry Market Trends, Size And Growth Analysis 2017 To 2022

Overview

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555336-recurrent-malignant-glioma-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 1 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Table of Contents

List of Figures
Introduction
Global Markets Direct Report Coverage
Recurrent Malignant Glioma - Overview
Recurrent Malignant Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Recurrent Malignant Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
AbbVie Inc
GtreeBNT Co Ltd
Recurrent Malignant Glioma - Drug Profiles .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555336-recurrent-malignant-glioma-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Latest Study Offers Detailed Insights On Acute Myelocytic Leukemia Industry 2017

Overview

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555334-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 98, 105, 1, 5, 171, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 16, 14, 31 and 13 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Table of Contents

Introduction 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 100
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles 218
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1600
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1612
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1616
Appendix 1628

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555334-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Global Therapeutic Landscape Of Rheumatoid Arthritis Industry Pipeline Review, 2017

Overview

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555332-rheumatoid-arthritis-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 17, 27, 48, 62, 7, 223, 52 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 37 and 12 molecules, respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.

Table of Contents

Introduction 10
Rheumatoid Arthritis - Overview 11
Rheumatoid Arthritis - Therapeutics Development 12
Rheumatoid Arthritis - Therapeutics Assessment 60
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 82
Rheumatoid Arthritis - Drug Profiles 194
Rheumatoid Arthritis - Dormant Projects 919
Rheumatoid Arthritis - Discontinued Products 948
Rheumatoid Arthritis - Product Development Milestones 955
Appendix 972

List of Tables
Number of Products under Development for Rheumatoid Arthritis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555332-rheumatoid-arthritis-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Recent Study Explores Vasomotor Symptoms of Menopause (Hot Flashes) Industry Pipeline Review, 2017

Overview

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555353-vasomotor-symptoms-of-menopause-hot-flashes-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 2 and 3 respectively.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Table of Contents

List of Figures
Introduction
Global Markets Direct Report Coverage
Vasomotor Symptoms of Menopause (Hot Flashes) - Overview
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development
EndoCeutics Inc
MenoGeniX Inc
Millendo Therapeutics Inc
Mithra Pharmaceuticals SA
Ogeda SA

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555353-vasomotor-symptoms-of-menopause-hot-flashes-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Female Contraception Industry Anticipated To Witness Noteworthy Growth In The Coming Years

Overview

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555351-female-contraception-pipeline-review-h1-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 3, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.

Table of Contents

List of Figures
Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Agile Therapeutics Inc
Bayer AG
Evofem Inc
Hervana Ltd
Mithra Pharmaceuticals SA

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555351-female-contraception-pipeline-review-h1-2017

About Us

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)